Oppenheimer added Alexandria Real Estate Equities to its preferred sell list, signaling increased Wall Street caution toward the life science REIT.
The downgrade reflects concerns over uncertain financing costs and a slowdown in biotech funding. These factors may lead to slower leasing decisions, potentially impacting net operating income and asset values.
Despite the rating change, Alexandria maintains a strong market position in key innovation hubs. The company also recently received recognition as a top employer for talent readiness.